

## Acknowledgement to Referees

© The Author(s) 2019

Dear Reader,

As we reach the final issue of *Drugs—Real World Outcomes* for 2019, we wish to reflect on another successful year's achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content.

2019 was a successful year for *Drugs—Real World Outcomes*. Over 20 articles have been published; the most popular of these, in terms of downloads from SpringerLink, have been:

Adverse Events Associated with Risperidone Use in Pediatric Patients: A Retrospective Biobank Study. Oshikoya, K.A., Carroll, R., Aka, I. et al. *Drugs—Real World Outcomes* (2019) 6: 59. <https://doi.org/10.1007/s40801-019-0151-7>

Patterns of High-Dose and Long-Term Proton Pump Inhibitor Use: A Cross-Sectional Study in Six South Australian Residential Aged Care Services. Hendrix, I., Page, A.T., Korhonen, M.J. et al. *Drugs—Real World Outcomes* (2019) 6: 105. <https://doi.org/10.1007/s40801-019-0157-1>

Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study. Sakata, Y., Matsuoka, T., Ohashi, S. et al. *Drugs—Real World Outcomes* (2019) 6: 27. <https://doi.org/10.1007/s40801-019-0150-8>

Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review. Joshi, R., Latremouille-Viau, D., Meiselbach, M.K. et al. *Drugs—Real World Outcomes* (2019) 6: 1. <https://doi.org/10.1007/s40801-018-0146-9>

A Benefit Risk Review of Pediatric Use of Hydrocodone/Chlorpheniramine, a Prescription Opioid Antitussive Agent for the Treatment of Cough. Sloan, V.S., Jones, A., Maduka, C. et al. *Drugs—Real World Outcomes* (2019) 6: 47. <https://doi.org/10.1007/s40801-019-0152-6>

Epidemiological Profile of Drug Overdose Reported in South-East Morocco from 2004 to 2016. Azekour, K., Belamalem, S., Soulaymani, A. et al. *Drugs—Real World Outcomes* (2019) 6: 11. <https://doi.org/10.1007/s40801-019-0148-2>

Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study. Lin, H.M.D., Lai, C.L., Dong, Y.H. et al. *Drugs—Real World Outcomes* (2019) 6: 93. <https://doi.org/10.1007/s40801-019-0156-2>

PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice. Parhofer, K.G., von Stritzky, B., Pietschmann, N. et al. *Drugs—Real World Outcomes* (2019) 6: 115. <https://doi.org/10.1007/s40801-019-0158-0>

We thank the authors who have contributed articles to *Drugs—Real World Outcomes* over the course of 2019. The skill and dedication of all authors are critical to the continued publication of the journal. The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal's content is held to the highest possible standard. We would like to thank the following individuals who acted as reviewers for *Drugs—Real World Outcomes* in the last 12 months:

Anabela Barcelos, Portugal  
 Francisco Batel-Marques, Portugal  
 Marc Buyse, Belgium  
 Pia Caduff-Janosa, Sweden  
 Camilla Callegari, Italy  
 Antonio Clavenna, Italy  
 Jacqueline Corrigan-Curay, USA  
 Benjamin Daniels, Australia  
 Roni P. Dodiuk-Gad, Israel  
 Khalid Eljaaly, Saudi Arabia  
 Andrea Fagiolini, Italy  
 Filipa Farinha, UK  
 Nicola Ferri, Italy  
 Daniel Fife, USA  
 Meghan Gabriel, USA  
 Armando Gonzalez-Ruiz, UK  
 Kaushik Guha, UK  
 Jan Hasselstrom, Sweden  
 Benjamin Hohlfelder, USA  
 Laurence G. Howes, Australia  
 Magnus Ingelman-Sundberg, Sweden  
 Aditi Kadakia, USA  
 Emily Karanges, Australia  
 Abhishek Kavati, USA  
 Farzin Khosrow-Khavar, Canada  
 Shunsuke Kiuchi, Japan  
 Roger Knaggs, UK  
 Eitaro Kodani, Japan  
 Georgios D. Kotzalidis, Italy  
 Gilles Lambert, France  
 Kathryn Lang, USA  
 Marie Linder, Sweden  
 Jette Möller, Sweden  
 Lubov Matchekkhina, Russia  
 Dídac Mauricio, Spain  
 Omid Mehrpour, Iran  
 Jose J. Mira, Spain  
 Pablo Mora, USA  
 Takatoshi Nawa, Japan  
 Khac-Dung Nguyen, France  
 Alexandra C. Pacurariu, The Netherlands  
 Vidhya Parameswaran, Canada  
 Klaus G. Parhofer, Germany  
 Wolfgang Philipp-Dormston, Germany  
 Sonam Puri, USA  
 Dima M. Qato, USA  
 Concetta Rafaniello, Italy  
 Lorenza Rimassa, Italy  
 Julie Rouette, Canada  
 Rafael Santana-Davila, USA  
 John D. Seeger, USA  
 Darshini Shah, USA  
 Michael D. Shapiro, USA  
 Caroline Sirois, Canada  
 Giuseppe Sito, Italy  
 Liberata Sportiello, Italy  
 Hema Sundaram, USA  
 Wade Thompson, Denmark  
 Sermin Toto, Germany  
 Joachim Veith, USA  
 Sigurd Vitols, Sweden  
 Kristie R. Weir, Australia  
 Dahlia Weitzman, Israel  
 Mike Wilcock, UK  
 Richard Willke, USA  
 Antoinette Wozniak, USA  
 Srikanth Yandrapalli, USA  
 Shan Yin, USA  
 Kazuki Yoshida, USA  
 Ulrich M. Zanger, Germany

In addition, we would like to thank the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:

G.C. Alexander, Johns Hopkins University, Baltimore, MD, USA  
 A. Beresniak, Data Mining International, Geneva, Switzerland  
 H. Birnbaum, Analysis Group, Inc., Boston, MA, USA  
 J. Bottomley, Amygdala Ltd., Letchworth Garden City, England  
 P. Denig, University of Groningen, Groningen, The Netherlands  
 J.E. Fincham, Presbyterian College School of Pharmacy, Clinton, SC, USA  
 B. Godman, Karolinska Institutet, Stockholm, Sweden  
 D. Goldsmith, Goldsmith Pharmacovigilance and Systems, New York, NY, USA  
 S. Karve, AbbVie, Chicago, IL, USA  
 C. Kozma, CK Consulting Associates, St. Helena Island, SC, USA  
 T. Lasky, U.S. Food and Drug Administration, Silver Spring, MD, USA  
 A.A. Mangoni, Flinders University, Adelaide, SA, Australia

---

S. Mimica-Matanovic, University Hospital Osijek, Osijek, Croatia  
P.G. Parmar, Auckland University of Technology, Auckland, New Zealand  
B. Rinaldi, University of Capania Luigi Vanvitelli, Naples, Italy  
J.K. Sluggett, Monash University, Parkville, VIC, Australia  
K.A. Swanson, University of Oklahoma, Oklahoma City, OK, USA  
F. van Hunsel, The Netherlands Pharmacovigilance Centre Lareb, Brabant, The Netherlands  
J.E Ware Jr., John Ware Research Group Incorporated, Watertown, MA, USA  
Q. Zou, Medstar Health Research Institute, Washington, DC, USA

We do hope that you have found the articles published throughout the year in *Drugs—Real World Outcomes* to be interesting and informative. The editorial schedule for 2020 is well under way, and we are looking forward to bringing you many high-quality and authoritative articles over the coming year.

With best wishes

Dene Peters (Editor) and Kathy Fraser (Deputy Editor)

**Open Access** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.